In T2DM patients, the combination of empagliflozin + metformin vs. metformin monotherapy ameliorated liver steatosis (with amelioration of 9% of the CAP value), ALT levels, body weight, and glycated haehemoglobinter only a 6-month follow-up. Here, GPT is linked to fatty liver disease.